Center for BioEnergetics, Biodesign Institute, Arizona State University, Tempe, AZ 85287, USA.
FASEB J. 2010 Jul;24(7):2152-63. doi: 10.1096/fj.09-143222. Epub 2010 Mar 10.
Friedreich's ataxia (FRDA) is a hereditary neurodegenerative disease that frequently culminates in cardiac failure at an early age. FRDA is believed to arise from reduced synthesis of the mitochondrial iron chaperone frataxin due to impaired gene transcription, which leads to mitochondrial iron accumulation, dysfunction of mitochondrial Fe-S containing enzymes, and increased Fenton-mediated free radical production. Recent reports have challenged this generally accepted hypothesis, by suggesting that the oxidative stress component in FRDA is minimal and thereby questioning the benefit of antioxidant therapeutic strategies. We suggest that this apparent paradox results from the radically divergent chemistries of the participating reactive oxygen species (ROS), the major cellular subcompartments involved and the overall cellular responses to ROS. In this review, we consider these factors and conclude that oxidative stress does constitute a major contributing factor to FRDA pathology. This reaffirms the idea that the rational design of specific small molecule multifunctional antioxidants will benefit FRDA patients.
弗里德里希共济失调(FRDA)是一种遗传性神经退行性疾病,通常会在早年导致心力衰竭。据认为,FRDA 是由于基因转录受损导致线粒体铁伴侣蛋白 frataxin 的合成减少,从而导致线粒体铁积累、线粒体 Fe-S 含酶功能障碍和增加 Fenton 介导的自由基产生。最近的报告挑战了这一普遍接受的假说,表明 FRDA 中的氧化应激成分最小,从而质疑抗氧化治疗策略的益处。我们认为,这种明显的悖论是由于参与的活性氧(ROS)、主要的细胞亚区室和细胞对 ROS 的整体反应的化学性质截然不同所致。在这篇综述中,我们考虑了这些因素,并得出结论,氧化应激确实是 FRDA 病理学的一个主要因素。这再次证实了这样一种观点,即合理设计特定的小分子多功能抗氧化剂将使 FRDA 患者受益。